BioNTech Archives -

News/ News/ News/ Patients/ Sales and Marketing

US government buys 66m doses of Moderna’s Omicron booster

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron, Pfizer, US 0 Comment

The Biden administration has confirmed its plans to start a booster vaccination campaign in the autumn, and placed

US government buys 66m doses of Moderna’s Omicron booster

https://pharmaphorum.com/news/us-government-buys-66m-doses-of-modernas-omicron-booster/

News/ News/ R&D

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Omicron, Pfizer 0 Comment

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

https://pharmaphorum.com/news/pfizer-takes-covid-jab-with-enhanced-spike-protein-into-phase-2/

News/ News/ Sales and Marketing

BioNTech bites back after CureVac patent challenge

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, CureVac, Moderna, patent litigation, Pfizer, Spikevax 0 Comment

BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine,

BioNTech bites back after CureVac patent challenge

https://pharmaphorum.com/news/biontech-bites-back-after-curevac-patent-challenge/

News/ News/ News/ Patients/ Sales and Marketing

Pfizer claims new $3.2bn COVID jab deal with US government

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Omicron, Pfizer, procurement, US 0 Comment

Pfizer and BioNTech have signed a new $3.2 billion supply contract with the US government for COVID-19 vaccines,

Pfizer claims new $3.2bn COVID jab deal with US government

https://pharmaphorum.com/news/pfizer-claims-new-3-2bn-covid-jab-deal-with-us-government/

Market Access/ News/ News/ News/ R&D

US panel backs Omicron-targeting vaccines for booster campaigns

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, fda, GlaxoSmithKline, Moderna, Novavax, Omicron, Pfizer, regulatory, variant 0 Comment

Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according

US panel backs Omicron-targeting vaccines for booster campaigns

https://pharmaphorum.com/news/us-panel-backs-omicron-targeting-vaccines-for-booster-campaigns/

Market Access/ News/ News/ News/ Patients

FDA advisors back COVID jabs for very young children

Phil Taylor access, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, paediatric, Pfizer, regulatory 0 Comment

The FDA’s vaccines advisors have voted in favour of extending the use of mRNA-based COVID-19 vaccine from Moderna

FDA advisors back COVID jabs for very young children

https://pharmaphorum.com/news/fda-advisors-back-covid-jabs-for-very-young-children/

Digital/ Views & Analysis/ Views and analysis

Pfizer: Pharma needs a business strategy for a digital world

mike.hammerton@pharmaphorum.com BioNTech, COVID-19, Digital transformation, Dominic Tyer, Pfizer 0 Comment

The unprecedented rate of digital acceleration seen in the first two years of COVID-19 has set in train

Pfizer: Pharma needs a business strategy for a digital world

https://pharmaphorum.com/digital/pfizer-pharma-needs-business-strategy-for-digital-world/

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

News/ News/ Patients

COV-BOOST trial data show value of fourth dose

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, Pfizer 0 Comment

Administering a fourth dose of an mRNA COVID-19 vaccine provides a stronger level of protection than a third

COV-BOOST trial data show value of fourth dose

https://pharmaphorum.com/news/cov-boost-trial-data-show-value-of-fourth-dose/

News/ News/ Oncology

AACR: BioNTech finds value in CAR-T/mRNA vaccine combo

Phil Taylor BioNTech, CAR-T therapies, claudin-6, immuno-oncology, mRNA, Oncology 0 Comment

Adding an mRNA vaccine to CAR-T cell therapy could be the key to unlocking activity in solid tumours,

AACR: BioNTech finds value in CAR-T/mRNA vaccine combo

https://pharmaphorum.com/news/aacr-biontech-finds-value-in-car-t-mrna-vaccine-combo/

Trending

BioNTech

Login